This article highlights the efficacy and safety data of denileukin diftitox-cxdl for the treatment of relapsed or refractory cutaneous T-cell lymphoma.
Yumena Kawasaki, PharmD, BCOP
Advertisement
Articles by Yumena Kawasaki, PharmD, BCOP
EPCORE trial data show epcoritamab plus lenalidomide and rituximab delivers responses in relapsed/refractory follicular lymphoma with outpatient dosing.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
State Pharmacy Boards Must Step Up Against Illegal Retatrutide
2
New CKD Outcome Set Tells Pharmacists What to Measure
3
GLP-1s and the HCM–Sleep Apnea–Obesity Connection
4
The PBM Reform Clock Is Running to 2028—Here's What Independent Pharmacies Should Do
5